MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'celgene'. Sat, 03 Sep 2011 02:38:13 +0100 http://www.medworm.com/index.php?rid=5107893&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FXpncqmok5No%2F Rise and shine. Another day is on the way. And it looks to be a sunny one here on the Pharmalot corporate campus, where we are brewing a delicious cup of mandatory stimulation. Our flavor today is Southern Pecan. Please join us. After all, there is much to do as meetings and deadlines beckon. You know the score, so time to dig in. Meanwhile, here are some tidbits. Have a great day and let us know if you hear of something interesting… FDA Approval Of Roche Melanoma Drug May Come Early (Reuters) Pfizer Sends Israeli Sniffing Dogs To Finland (The Jerusalem Post) Revlimid Side Effects Linked To Protein In Study (Reuters) Valeant Pharma Eyes Medicis For Another Acquisition (Pharma Times) Merck And J&J Sit On Piles Of Cash (The Star-Ledger of New Jersey) Lexicon Tumor Drug Shows Posit... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=5107893 Tue, 09 Aug 2011 12:06:27 +0100 5107893 http://www.medworm.com/index.php?rid=4945197&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F6lF6tGbTdbE%2F And so, another working week is about to draw to a close. This is, of course, our signal to daydream about weekend plans. For now, we intend to do some reading, catch up with our short people and promenade with the official Pharmalot mascots. And you? Anything special? Perhaps a drive in the country? A chance to meet with friends? Or maybe balance your checkbook and show the indebted nations how it’s done? Whatever your fancy, have a great time. Oh, and say ‘hi’ to Dad… FDA Reviewers Say Novartis Gout Drug Data Is Complicated (Reuters) Roche Faces Significant Hurdles For Avastin Breast Cancer Indication (Financial Times) UK Officials Say Pfizer Doing ‘Too Little’ As Plant Closes (BBC) FDA Approves Expanded Use Of Celgene Lymphoma Drug (Reuters) AstraZene... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4945197 Fri, 17 Jun 2011 12:15:14 +0100 4945197 http://www.medworm.com/index.php?rid=4853220&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F_HzGxgsWQUM%2F As countless researchers and marketers gear up for the American Society of Clinical Oncology meeting in early June to review breakthroughs and close calls, one issue may warrant further inspection - the cost of these cancer meds and how patients are reacting. Why? A new analysis shows that 10 percent of patients are abandoning prescriptions for their oral cancer drugs. The reasons: higher cost-sharing for insurance coverage, a larger number of overall prescriptions for different medications, Medicare coverage and incomes, according to Avalere Health, which reviewed pharmacy transaction data between 2007 and 2009, and will present its paper at ASCO next month. The study was published in the Journal of Oncology Practice and American Journal of Managed Care (here is the abstract). To be speci... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4853220 Mon, 23 May 2011 12:54:56 +0100 4853220 http://www.medworm.com/index.php?rid=4522291&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FEacgP4fZABY%2F And so another work week is about to draw to a close. And this means daydreaming about the weekend. Our agenda includes visiting with a favorite aunt and uncle, taking the short people to assorted sports activities and tackling our overwhelming to-do list. What about you? Will you make time to exercise? Catch a movie? You can always prepare your taxes (and perhaps your payments could narrow the deficit). Whatever you do, be safe and have a wonderful time. See you soon… Samsung And Quintiles Partner To Make Biologics (Bloomberg News) Elan And Celgene Settle Patent Lawsuit Over Abraxane (Reuters) Plague Kills Scientist In First Lab Case In 50 Years (Bloomberg News) UK Gang Jailed For Counterfeit Mecidines Plot (Securing Pharma) FDA Rejects Pfizer And Protalix Med For Gaucher’s (B... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4522291 Fri, 25 Feb 2011 13:04:10 +0100 4522291 http://www.medworm.com/index.php?rid=4507581&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FNvoAwJK_fUk%2F Oncology is a big market and getting bigger, of course, but which drugmaker ranks highest is most effective in reaching oncologists? A recent poll of 475 medical and hematological oncologists found that Novartis commands a leading 12.5 share of details, although its position slipped slightly from the previous year, while Roche jumped from 10 percent to 12 percent thanks to combining sales teams with Genentech. Meanwhile, Sanofi-Aventis slid from 8 percent to about 6.5 percent thanks to looming patent expirations for Taxotere and Eloxatin, according to ImpactRx, a market research firm. In line with the results, Genentech tied with OSI Pharmaceuticals as the drugmaker with a top tier sales force, followed by Biogen Idec, Amgen, Eli Lilly and Celgene (here is the report). For the second year ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4507581 Tue, 22 Feb 2011 14:08:29 +0100 4507581 http://www.medworm.com/index.php?rid=4489977&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FTtqj3J1HvPI%2F Hello and nice to see you again. Having successfully deposited one of the short people at the local schoolhouse, we are celebrating with yet another cup of stimulation. Please join us or grab a bottle of water, if you prefer, and get ready for another day of meetings and deadlines and who-knows-what-else. Meanwhile, here are some fresh tidbits. Have a good one and stay in touch… China To Help Domestic Drugmakers Expand Overseas (Global Times) AstraZeneca Pays $150M To Settle More Seroquel Lawsuits (Bloomberg News) Amgen Haunted By Medicare Worries (Forbes) Glaxo Cuts Neuroscience Jobs In North Carolina (MedCity News) UK’s NICE Endorses Celgene Blood Cancer Med (Reuters) Allergan Wins Wider Use For Lap-Band Device (Wall Street Journal) EU Parliament Approves Tougher Counterfeit ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4489977 Thu, 17 Feb 2011 13:03:30 +0100 4489977 http://www.medworm.com/index.php?rid=4382948&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FEIoAa660t8g%2F For nearly four years, Celgene has been locked in a dispute with Canada’s Patented Medicine Prices Review Board over the agency’s insistence on getting pricing info for Thalomid. At issue: Celgene was selling its Thalomid treatment at a higher price in Canada than elsewhere and the board maintained that it has jurisdiction to order Celgene to lower its price (see the board decision). After all, Health Canada gave the board the power to review international pricing info of patented drugs sold in Canada to protect consumers from excessive prices. But Celgene argued Thalomid was sold at its New Jersey plant and shipped to Canadian docs, and so the board does not have jurisidiction. Celgene then yanked the drug and won a federal court decision, sending the dispute went all the way to t... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4382948 Fri, 21 Jan 2011 15:19:35 +0100 4382948 http://www.medworm.com/index.php?rid=4314221&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F6v6OHNUJQ_Y%2F Greetings, everyone. How are you this morning? We trust you feel invigorated as another day gets under way. As usual, we are brewing a delicious cup of stimulation and poking around for interesting items. Heard something fascinating? Send us a note. Meanwhile, we hope your workload is manageable and much gets accomplished. Catch you soon… Pfizer Faces 1,200 Chantix Lawsuits (Birmingham News) Spectrum To Make Biosimilar Of Roche’s Rituximab (Reuters) Roche Wins Wider Approval For Actemra (Bloomberg News) Evidence Links Avastin To Heart Failure In Breast Cancer Patients (HealthDay) EMA Worries Over Foreign APIs (InPharma-Technologist) J&J Files For FDA Approval Of Bloodthinner (Associated Press) Celgene Submits New Applications For Cancer Meds (Reuters) Xoma Inks $505M Diabe... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4314221 Wed, 05 Jan 2011 12:48:44 +0100 4314221 http://www.medworm.com/index.php?rid=4266264&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FSZ-Te091wg0%2F And so another working week draws to a close, which means the time has come to daydream, just a little, about our weekend plans - a brisk walk with the official Pharmalot mascots, spending time with our short people and taking a nap or two. What about you? Will you brave the shopping crowds? Curl up with your favorite e-book reader? Connect with a special person? Whatever you do, we hope you have a pleasant time. Meanwhile, here are some tidbits to jumpstart the day. Stay in touch…. Merck Extends Deadline For Closing Organon Dutch Facilities (Reuters) Your Pharmaceutical Cargo Theft Update (Securing Pharma) Celgene Raises Revlimid Price To $85K A Year (Dow Jones) FDA Considers Generic User Fees (Pittsburgh Post-Gazette) Sanofi-Aventis And Merck KGgA Sign Cancer Drug Deal (Bloomberg N... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4266264 Fri, 17 Dec 2010 12:44:28 +0100 4266264 http://www.medworm.com/index.php?rid=4106058&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fp0__1ar8-tk%2F Hello, everyone, and a very good morning to you. Another shiny day is unfolding here on the Pharmalot corporate campus, where we are hustling assorted short people off to the local schoolhouse and preparing for the usual round of meetings and deadlines. Same with you? Of course. So to prepare, here are a few items of interest. Hope your day goes well and do stay in touch… Savient Pharmaceuticals Fails To Find A Buyer (Bloomberg News) Boehringer Prices New Bloodthinner At $6.75 A Day (Reuters) Celgene Scales Back Expansion Plan (NJ.com) Walgreen May Sell Its PBM Business (Bloomberg News) Insurer Pilots Cancer Care Reimbursement For Oncologists (PharmaTimes) NICE May Not OK Simponi For Rheumatoid Arthritis (PharmaTimes) Amgen Earnings Beat Estimates Despite Shrinking Sales (Bloomberg N... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4106058 Tue, 26 Oct 2010 12:03:44 +0100 4106058 http://www.medworm.com/index.php?rid=3911869&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FGf8L4iGDbFc%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something that’s become a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that the AbelsonTaylor advertising agency that specializes in healthcare, promoted Barry Levine to creative director. A 19-year veteran of pharma advertising, he joined the agency in 1998, serving most recently as associate c... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3911869 Fri, 27 Aug 2010 12:25:59 +0100 3911869 http://www.medworm.com/index.php?rid=3907785&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FnOh-g8JZPUg%2F A sunny day is unfolding here on the Pharmalot corporate campus, where the mascots are happily frollicking among the weeds. As for us, we are brewing the mandatory cup of stimulation. What about you? Heading off toward your own campus? Prepping for those meetings and deadlines? Whatever you encounter, we hope your day goes well. One housekeeping note: we will break early today to shuffle one of the short people off to an institution of higher learning. See you soon… Advanced Melanoma Treatment Shrinks Tumors: Study (Reuters) Cephalon CEO Takes A Medical Leave Of Absence (Bloomberg News) Drugmakers Experiment With Design (The Financial Times) Celgene Has Been Plotting Revlimid Challenge (The Wall Street Journal) CVS/Caremark Closes Mail-Order Facility And Cuts 400 Jobs (The Birmingham... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3907785 Thu, 26 Aug 2010 11:32:58 +0100 3907785 http://www.medworm.com/index.php?rid=3519710&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F4B6g7P-pE6M%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something we hope to make a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that that Qforma, which traffics in analytics and predictive modeling, hired Judy Stein as director of client services. She most recently worked as a senior manager at GE Healthcare’s Performance Solutions unit, where s... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3519710 Fri, 30 Apr 2010 11:56:30 +0100 3519710 http://www.medworm.com/index.php?rid=3515298&cid=t_134760_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2010%2F04%2Foh-prices-we-pay-reloaded-celgene-balks.html A brief article on Bloomberg.com implied that Celgene has been fighting efforts by the Canadian Patented Medicine Prices Review Board to get pricing data about the drug Thalidomid (thalidomide):Celgene Corp., the biotechnology company specializing in blood-cancer medicines, will get a hearing before Canada’s highest court over the country’s demands to provide pricing information for the drug Thalomid.The Supreme Court of Canada today agreed to hear Celgene’s appeal of a Federal Court of Appeal ruling that said Canada’s Patented Medicine Prices Review Board was entitled to information about the pricing of the drug. The high court gave no reason for its decision.Celgene’s two top-selling drugs are Revlimid and Thalomid, for a form of blood-cancer called multiple myeloma. They broug... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=3515298 Wed, 28 Apr 2010 19:57:00 +0100 3515298 http://www.medworm.com/index.php?rid=3499308&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FEyBkqr9b-FE%2F Pricing is always a touchy subject. Celgene, however, is taking this to a new level. The drugmaker is battling Canada’s Patented Medicine Prices Review Board over its insistence on getting pricing info for Thalomid. Last December, a federal court ruled the agency was entitled to the data, but Celgene appealed and the Supreme Court of Canada has agreed to hear the appeal, Bloomberg News reports. A federal appeals court ruled last December that the review board “has a legitimate interest” in the cost of the med because the price will be paid “by the ultimate consumer in Canada.” But Celgene has a unique argument - since Thalomid was sold at its New Jersey plant and shipped to Canadian docs, Celegene says the review board doesn’t have jurisdiction to demand anything. T... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3499308 Fri, 23 Apr 2010 11:45:10 +0100 3499308 http://www.medworm.com/index.php?rid=3487317&cid=t_134760_136_f&fid=36162&url=http%3A%2F%2Fwww.myelomablog.com%2F2010%2F04%2F19%2Fw5-investigates-the-high-cost-of-celgenes-thalidomide%2F http://watch.ctv.ca/news/w5/pills-patients–profits/#clip281624 Canada’s news program, W5 (which I assume is shorthand for who, what, when, where and why) , did a program called, “Pills Patients & Profits.”  You can see the entire segment on their web site.  Click on the link or image above to watch part 3, which focuses on the cost of thalidomide (Celgene’s Thalomid), which is an important treatment for multiple myeloma. It’s very informative, so please do watch all four parts. (Source: beth's myeloma blog) beth's myeloma blog blogs http://www.medworm.com/rss/comments.php?id=3487317 Mon, 19 Apr 2010 17:18:14 +0100 3487317 http://www.medworm.com/index.php?rid=3454199&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FAAWTYIbFkQc%2F Once again, another working week will soon draw to a close. We are actually finishing out a vacation day and so posting will be abbreviated this morning as we pack our travel gear and hustle one of the short people along the winding road home. Nonetheless, we have located a few interesting items that may have missed your attention. Meanwhile, we hope you have a nice weekend, whatever you do. See you soon and stay in touch… Novartis Reps Say They Were Cheated (Associated Press) Glaxo To Keep Upstate NY Plant, But Close NJ Plant (The Albany Business Review) Celgene Says Stem Cell Therapy Met Safety Goal (Associated Press) photo thx to kossy@finedays flickr (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3454199 Fri, 09 Apr 2010 12:15:02 +0100 3454199 http://www.medworm.com/index.php?rid=3331606&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2F2p96dNLfh5Q%2F Hello, everyone. How are you today? Bracing for deadlines and meetings, no doubt. We understand. Our immediate challenge is rousting one of the short people from a deep slumber. To cope, we are brewing the ritual cup of stimulation and searching for interesting items. Here are a few, in fact, to help you along. Have a good day and stay in touch… Dendreon’s Provenge Boosts Survival 40 Percent (Reuters) Sanofi Prostate Cancer Drug May Set New Standard (TheStreet) Child Seizure Study Finds Older Drugs Work Best (Reuters) Hospital Takes Huge Mark-Up On Roche’s Avastin (Bloomberg) UK’s NICE Spurns Celgene Rare Blood Cancer Drug (Reuters) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3331606 Thu, 04 Mar 2010 12:08:47 +0100 3331606 http://www.medworm.com/index.php?rid=3101064&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FNJXjaAU31_U%2F Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going, especially with all the layoffs. Despite the downsizing, there is movement. Here are some of the latest changes. Recognize anyone? And here is something we hope to make a regular feature. Send us a photo and we will spotlight a different person each week. This time around, we note that Merck hired Michael Rosenblatt as executive vice president and chief medical officer. He’s been the dean of Tufts University School of Medicine since 2003 and before that, was a professor of medicine at Harvard Med... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3101064 Fri, 18 Dec 2009 11:39:33 +0100 3101064 http://www.medworm.com/index.php?rid=3063474&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FHjCrS3U1brs%2F Welcome to the working week. We hope your weekend was pleasant and invigorating. Now, though, the routine returns. And with it come the usual onslaught of meetings, deadlines and projects. So grab a cup of stimulation and get ready. To help you along, here are a few items of interest. Hope your day is tolerable… Celgene To Buy Gloucester In $640M Deal (Associated Press/nj.com) Glaxo Launches $15M Ad Campaign For Nicorette (Forbes) Roche Family Holdings Decline (MPT Online) Rexahn Pharma Looks For A Big-Pharma Deal (Washington Business Journal) Drugmakers Propose Plan To Curb Opioid Misuse (Associated Press) Data Exclusivity Causes Debate In India (The Business Standard) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3063474 Mon, 07 Dec 2009 13:05:47 +0100 3063474 http://www.medworm.com/index.php?rid=2959031&cid=t_134760_136_f&fid=36162&url=http%3A%2F%2Fwww.myelomablog.com%2F2009%2F11%2F03%2Fmyeloma-treatment-drugs-celgene%2F Probably most of us who’ve had treatment for our myeloma have been prescribed one of the drugs manufactured by Celgene.   Celgene makes Revlimid® (lenalidomide) and Thalomid® (thalidomide). That really annoying guy on TV, Jim Cramer (Mad Money, CNBC), says it’s on his list of stuff to buy.   According to the CNBC site: So when do you buy CELG? Cramer said that investors could wait until the annual American Society of Hematology (ASH) meeting on Dec. 5, where Celgene is expected to present “some terrific Revlimid data.” “I wouldn’t pull the trigger on this trade until the week before the conference,” Cramer said. http://www.cnbc.com/id/33603726 I’ll be waiting to see what happens during the ASH conference. Possibly Related Posts: If you’re sick, ... beth's myeloma blog blogs http://www.medworm.com/rss/comments.php?id=2959031 Wed, 04 Nov 2009 01:47:56 +0100 2959031 http://www.medworm.com/index.php?rid=2415794&cid=t_134760_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2009%2F05%2F15%2Fcg%2F A likely backup to CG-930, its a Signal discovered JNK inhibitor for which there is a solid forms app: WO/2008/057252 - no mention of stereochemistry - Posted in Celgene, Jnk (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=2415794 Sat, 16 May 2009 02:21:40 +0100 2415794 http://www.medworm.com/index.php?rid=1996960&cid=t_134760_136_f&fid=36162&url=http%3A%2F%2Fmyelomablog.com%2F2008%2F11%2F27%2Fthalidomide-celgene-and-the-high-cost-of-staying-alive%2F By Dennis Hemus Many Multiple Myeloma patients have been damaged by the high cost of drug treatment and worse some do not receive treatment at all because of cost. The following is a brief summary of how I came to intimately know the drug Thalidomide and the journey it has taken me on. I was diagnosed early in 2001 at the age of 54 and underwent an Autologous Stem Cell Transplant that summer. The result was fantastic. Life with my family was back to normal and my recovery was so complete I could play hockey, backpack and do physical work as I did pre MM. I was the happiest guy in town. The cancer slowly gained another foot hold and in January of 2005 I had a second SCT but that one did not work and I was in trouble! My Calgary Oncologist suggested that I try Thalidomde. (In Canada procedur... beth's myeloma blog blogs http://www.medworm.com/rss/comments.php?id=1996960 Fri, 28 Nov 2008 00:52:05 +0100 1996960 http://www.medworm.com/index.php?rid=1955507&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F449466213%2F Nice to you see again, too. A nippy start here on the Pharmalot corporate campus, where the heat seems to be missing in action. Nonetheless, we must persevere as we transport the short people to their schoolhouses. Meanwhile, we have found a few items that may generate some heat of their own… Indiana Woman Sues Pfizer Over PCB Contamination (The Tribune-Star) Celgene Stem Cell Therapy Gets FDA OK For Human Trials (Reuters) Merck/J&J Recall Infant Gas Drops (Bloomberg News) New Zealand Court Tells AstraZeneca To Comply With Inquiry (news3) Glaxo, XenoPort Yank Restless Leg Drug Application (Associated Press) Large Malaria Trial To Begin In Africa (Associated Press) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1955507 Tue, 11 Nov 2008 12:05:02 +0100 1955507 http://www.medworm.com/index.php?rid=1918201&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F434593179%2F Revlimid can extend the lives of patients with an aggressive cancer of the bone marrow by up to three years, but draft guidance from the UK’s National Institute of Health and Clinical Excellence has said it is not cost effective and the estimate of three years of extra life was disputed, The Telegraph reports. The med is used to treat Myeloma, an incurable bone marrow cancer that cuts production of red and white blood cells. An estimated 20,000 people in the UK have the disease and each year around 3,800 new cases are diagnosed. The cancer has a high mortality rate, claiming more than 2,400 lives a year. But Revlimid costs $56,400 per patient per year and breaches the cost effectiveness threshold used by NICE more than twice over, the paper writes. Charities are now calling for the... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1918201 Tue, 28 Oct 2008 10:41:24 +0100 1918201 http://www.medworm.com/index.php?rid=1779672&cid=t_134760_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2008%2F09%2F09%2Fjnk-science%2F Roche Palo Alto just published 3E7O: JNK2 (7x mutant) bound to an indazole: Which brings up that nearly two years ago I suggested CC-401 may be from an ‘06 Celgene application.  Right flavor wrong compound, the drawn compound is CG-930 (IND filed Dec 18, 2007 - claimed in Ph1 for fibrotic diseases).  As NCI suggests CC-401 is an SP-600125 analog which incidentally is no longer on the CG pipeline.   That’s life on the edge for yah. (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=1779672 Wed, 10 Sep 2008 02:36:47 +0100 1779672 http://www.medworm.com/index.php?rid=1212318&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F230337736%2F In a letter to Pharmion ceo Pat Mahaffy, Steven Cohen’s SAC Capital advisors contends that the biotech could be worth more as a standalone company than Celgene’s $2.9 billion offer, depending upon the results of a clinical trial for a rival’s key drug. MGI Pharma is testing Dacogen, a cancer med similar to Pharmion’s Vidaza, which is used to treat MDS, a bone marrow disease. SAC and its affiliates hold an 8.3 percent stake in Pharmion. “Based on our own analyses and those in the published research of numerous sell-side analysts, we believe that if Dacogen’s survival data are worse than Vidaza’s, Vidaza could capture significantly more than half of the MDS market and peak sales could be $100 million to $250 million higher than current projectionsm,&... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1212318 Wed, 06 Feb 2008 14:58:48 +0100 1212318 http://www.medworm.com/index.php?rid=1191569&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F226564699%2F Wyeth forecast flat revenue and lower earnings for this year due to generic competition for its blockbuster Protonix heartburn med and other generic competition. The forecast hinges on keeping R&D spending flat and trimming other expenses, such as 10 percent of its workforce. The drugmaker reported fourth-quarter earnings rose to $1 billion, or 75 cents, from $855 million, or 63 cents, a year ago, on higher sales of its Enbrel arthritis drug and Prevnar vaccine. Excluding one-time items, profits were 78 cents. Revenue rose 10 percent to $5.8 billion. Read more here and here. Bristol-Myers Squibb narrowed its loss in the fourth quarter thanks to rising sales of its Plavix bloodthinner, which partially offset charges including investments backed by sub-prime securities. Net loss was $89... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1191569 Thu, 31 Jan 2008 14:17:34 +0100 1191569 http://www.medworm.com/index.php?rid=1176188&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F222535587%2F Another day, another to-do over Vytorin. Here an investigation. There an investigation. Everywhere an investigation. Still, as interesting as the controversy may be, other matters continue to attract us. It’s a big world, after all (look to the left). So here are a few that spun off… Amgen Posts Anemia Profit On Drop In Anemia Drug Sales (Bloomberg News) European Panel Doesn’t Recommend Celgene’s Revlimid (Yahoo/Reuters) Glaxo To Add Warning To Avandia Label In Europe (Thomson Financial) Pfizer Launches New Poultry Division (The Poultry Site) Ranbaxy Seeks Acquisitions To Bolster Indian Market Share (Bloomberg News) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1176188 Thu, 24 Jan 2008 22:18:57 +0100 1176188 http://www.medworm.com/index.php?rid=1170213&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F221226074%2F Another busy day here in the nation’s medicine chest. Here are a few stray items that have come to our attention… A famed punk rocker claims his life has been ruined by addiction to Glaxo’s Paxil. Kirk Brandon, best known for his time with 1980’s legends Spear of Destiny, is claiming up to $100,000 following undisclosed personal injuries, The Argus reports. Brandon claims ‘discontinuation syndrome’ caused addiction. Glaxo is contesting the charge. Pharmion employees will get bonuses for staying while its acquisition by Celgene is being completed, The Denver Business Journal writes. Anyone hired by the Nov. 18 announcement of the $2.9 billion deal will qualify to receive pay 25 percent above their normal salary for staying until June 1; staying between th... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1170213 Tue, 22 Jan 2008 21:44:21 +0100 1170213 http://www.medworm.com/index.php?rid=1085980&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F198368248%2F A late sign-off this evening due to various errands and time spent with the short people. Nonetheless, the world keeps spinning and here are a few items that came our way. And please remember to vote in our reader poll (click here) about whether an OTC version of the Mevacor cholesterol pill is a good idea… Amgen, J&J Amgen Drugs Show Higher Leukemia Risk (Bloomberg News) Celgene Stock Plunges After Disappointing Revlimid Study (Bloomberg News) Muddled Data Hurts Medarex Shares (TheStreet.com) Novo Nordisk Settles Patent Dispute With Pfizer (The Guardian/Reuters) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1085980 Tue, 11 Dec 2007 02:21:27 +0100 1085980 http://www.medworm.com/index.php?rid=1034913&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F186874421%2F The up-and-coming drugmaker is paying a hefty premium in this cash and stock deal - Celgene is agreeing to pay $72 a share, way above the $49.28 closing price on Friday (interestingly, Pharmion shares closing up nearly 5 percent for the day and continued rising in after-hours trading). But Celgene sought the deal because the move furthers its goal of marketing both oncology and hematology meds. “The acquisition of Pharmion is an exceptional strategic fit that will expand our role as a leader in hematology and oncology,” says Sol Barer, Celgene’s ceo and chairman, in a statement. “Our combined global infrastructure will leverage the therapeutic and commercial potential of Pharmion’s products, particularly Vidaza, which has the potential to become a major global... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1034913 Sun, 18 Nov 2007 23:34:40 +0100 1034913 http://www.medworm.com/index.php?rid=985661&cid=t_134760_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F10%2F27%2Fwo2007084560%2F Celgene S.D. aka Signal has a series of v600e active thienopyrimidines that also appear to hit the non-kinase PDE4. WO/2007/084560 (NH2 > S) (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=985661 Sun, 28 Oct 2007 03:06:43 +0100 985661 http://www.medworm.com/index.php?rid=977432&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F174822466%2F A rainy morning here in the nation’s medicine chest. Even so, there are always rays of sunshine emanating from the news. So grab a cup of coffee or tea and enjoy the warmth… Europe Opens Its Doors To Cheaper Biogenerics (The Chicago Tribune) ImClone Profits Fall On Charge (Yahoo/AP) Celgene Earnings Rise On Higher Sales (Yahoo/Reuters) And here are a couple of interesting tales you may have missed…. The indefatigable Amgen ceo, Kevin Sharer, who doesn’t know a crisis when he sees one, hopes that a new drug, denosumab, could become a “double blockbuster,” both as a twice-a-year treatment for osteoporosis and as a remedy for cancers of the bone. And so Forbes writes that for denosumab to succeed, Amgen will have to battle with Novartis and its once-a-year ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=977432 Thu, 25 Oct 2007 11:40:35 +0100 977432 http://www.medworm.com/index.php?rid=900986&cid=t_134760_149_f&fid=35786&url=http%3A%2F%2Fkinasepro.wordpress.com%2F2007%2F09%2F25%2Farray-bag-o-cash-en-route%2F 40M up front: …Array will grant Celgene an option to select drugs developed under the collaboration that are directed to two of four mutually selected discovery targets… Looks like unpartnerds include: KSP, P38, P38/tie2, Erbb1-2,  RAF, TLR’s, etc… (Source: KinasePro) KinasePro blogs http://www.medworm.com/rss/comments.php?id=900986 Tue, 25 Sep 2007 12:11:35 +0100 900986 http://www.medworm.com/index.php?rid=894335&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F160564679%2F And so we all return from the weekend. Hope yours was enjoyable. Ours was splendid. We managed to mow the lawn yesterday, a rare event that met with the approval of the neighbors (not that we care all that much). And we took the shortest of the short people on a hayride to pick a few pumpkins. Now, though, we are again scouring the world for interesting insights. Here are a few of the latest… EU Delays Schering-Plough, Organon Review For Two Weeks (CNNMoney/Dow Jones) EU Approves Pfizer’s Selzentry AIDS Drug (Yahoo/Reuters) Glaxo Wins EU Approval To Sell Cervarix HPV Vaccine (Bloomberg News) Novartis’ Exelon Alzheimer’s Patch Approved By EU (CNN/Thomson Financial) Lilly Sues Sun Pharma To Block Generic Version Of Strattera (Bloomberg News) FDA Delays Approval Of Gla... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=894335 Mon, 24 Sep 2007 11:10:00 +0100 894335 http://www.medworm.com/index.php?rid=758804&cid=t_134760_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F137582446%2F Bristol-Myers Squibb says profit rose 5.8 percent after its top-seller, the Plavix blood thinner, recaptured market share from a generic and sales increased for its schizophrenia and HIV drugs. Second-quarter net income rose to $706 million, or 36 cents, from $667 million, or 34 cents, a year ago. Revenue rose 1.2 percent to $4.93 billion, led by a 27 percent jump for the Abilify schizophrenia pill Abilify. Earnings excluding some items matched analysts’ estimates, and Bristol raised its forecast. “With the Plavix patent no longer in jeopardy, Bristol’s business fundamentals look solid,”‘ said Roberto Cuca, an analyst with JPMorgan in New York, in a note to clients, Bloomberg News writes. “Bristol appears to have a stable of products that should begin t... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=758804 Thu, 26 Jul 2007 12:08:09 +0100 758804